Satellite Symposium HER2+ Early Breast Cancer Therapy: Good, Better, Best - Never Let it Rest! Friday, April 21 – 3:45-5:15 p.m. Cascade Room, The Fairmont Banff Springs Speakers: Dr. Anil Abraham Joy MD, FRCPC Professor, Department of Oncology, Division of Medical Oncology, University of Alberta Medical Oncologist, Cross Cancer Institute, Edmonton, Alberta, Canada Colleen Olson BA, BSP Senior Oncology Pharmacist, Saskatoon Cancer Centre Description: Breast cancer remains the most commonly diagnosed cancer in women and is the leading cause of cancer-related deaths. Despite current advances in HER2-positive early breast cancer treatments, up to one in three women with HER2-positive early breast cancer will develop metastatic disease. This session will focus on the evolution of HER2-targeted therapies in early breast cancer and the potential role of novel agents in HER2-positive breast cancer from the perspective of a multi-disciplinary team. Learning Objectives: 1. Review the historical outcomes in the pre-trastuzumab era, the trastuzumab revolution and optimization of trastuzumab therapy 2. Examine the role of novel agents/therapeutic strategies in early HER2-positive breast cancer 3. Understand the mechanism of action, common toxicities, and pharmacy consideration in administration of HER-targeted therapies 4. Discuss the role of pharmacists in early breast cancer patient practice CAPhO Conference 2017 Support for this satellite symposium is provided by Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8 Canadian Association of Pharmacy in Oncology April 20 – 23, 2017 The Fairmont Banff Springs Hotel, Banff, Alberta